Bryn Mawr Trust Advisors LLC Sells 4,488 Shares of Zoetis Inc. $ZTS

Bryn Mawr Trust Advisors LLC reduced its position in Zoetis Inc. (NYSE:ZTS) by 30.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 10,181 shares of the company’s stock after selling 4,488 shares during the period. Bryn Mawr Trust Advisors LLC’s holdings in Zoetis were worth $1,490,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC grew its stake in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares in the last quarter. REAP Financial Group LLC lifted its position in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares in the last quarter. NewSquare Capital LLC boosted its holdings in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. Financial Consulate Inc. purchased a new position in shares of Zoetis in the third quarter valued at $39,000. Finally, SJS Investment Consulting Inc. grew its position in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of ZTS opened at $124.79 on Friday. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The company has a market cap of $54.99 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 2.10 and a beta of 0.97. The stock has a 50-day moving average price of $124.08 and a 200-day moving average price of $137.15.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the firm posted $1.58 earnings per share. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is presently 35.69%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ZTS. Morgan Stanley set a $160.00 price objective on Zoetis in a report on Thursday, December 18th. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday. Barclays started coverage on shares of Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Finally, Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price on the stock. in a research note on Monday, December 15th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $152.45.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.